
|Videos|July 15, 2021
Metastatic urothelial carcinoma: Is addition of more therapies to treatment regimens beneficial?
Author(s)Urology Times staff
Shilpa Gupta, MD, discusses several recent studies in the metastatic urothelial carcinoma space.
Advertisement
In this video, Shilpa Gupta, MD, discusses how recent research appears to indicate that the addition of more agents is not beneficial to patients undergoing treatment for metastatic urothelial carcinoma. Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5


















